The effect was not dependent on upregulated expression of the co-stimulatory molecules CD80 or CD86 ... producing T cells, whereas addition of exogenous IL-2 during T cell priming by LSECs ...

Emergex looks forward to this important next step in the development of its novel T cell-priming Betacoronavirus candidate. NIAID is projected to cover the full cost of the Phase I clinical trial ...